Trial Profile
An open-label, randomized, two-period crossover study to compare the pharmacokinetic and safety profile of single dose of TAK-070 (50 mg) under fed and fasting condition in healthy volunteer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs TAK 070 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- 24 Feb 2017 Status changed from not yet recruiting to completed.
- 25 Jun 2015 New trial record